In mammals, a large number of enzymes exist that metabolize drugs and other xenobiotics. Cytochrome P450s are among the most important of these enzymes that are involved in metabolism of most therapeutically-used drugs. In addition, P450s catalyze the metabolic-activation of chemical carcinogens. The P450s involved in xenobiotic metabolism are found in the CYP1, CYP2 and CYP3 families. Each of these families consist of two or more subfamilies. The fact that P450s can metabolically-activate toxins and procarcinogens in vitro implies that they are involved in toxicity and cancer. However, it is not known whether P450s are required for the toxicity and carcinogenicity of chemicals in an intact animal. The only experiments suggestive of a role for P450s in cancer etiology are indirect chemically-induced transformation assays in cell culture, and genetic experiments in mice involving the Ah locus. No direct evidence is available to establish that P450s are necessary for carcinogenesis in an intact animal model system. To assess the potential contribution of P450s to acute chemical toxicity and the process of chemical carcinogenesis, and to determine their roles, if any, in mammalian development and physiological homeostasis, P450-null mice were produced. Mice lacking expression of other carcinogen metabolizing enzymes like the microsomal epoxide hydrolase (mEH) and the quinone oxidoeductase (NQO1) were also made. Studies with CYP1B1-null mice have revealed that this P450 is required for the carcinogenic efforts of polycyclic aromatic hydrocarbons. Mice lacking mEH are also sensitive to the carcinogens thus indicating that the classic diol-epoxide route of carcinogen activation is the most important or carcinogenesis in vivo. In order to produce mouse models that can more accurately be used to predict human drug and carcinogen metabolism, P450-humanized mice are being prepared using bacterial artificial chromosomes. Transgenic mice carrying the human genes will be bred with P450 null-mice to produce humanized mice. Mice expressing human CYP2D6 have been produced and others are under preparation.

Agency
National Institute of Health (NIH)
Institute
Division of Basic Sciences - NCI (NCI)
Type
Intramural Research (Z01)
Project #
1Z01BC005562-15
Application #
6761569
Study Section
(LM)
Project Start
Project End
Budget Start
Budget End
Support Year
15
Fiscal Year
2002
Total Cost
Indirect Cost
Name
Basic Sciences
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Cheng, Jie; Krausz, Kristopher W; Li, Feng et al. (2013) CYP2E1-dependent elevation of serum cholesterol, triglycerides, and hepatic bile acids by isoniazid. Toxicol Appl Pharmacol 266:245-53
Holmstock, Nico; Gonzalez, Frank J; Baes, Myriam et al. (2013) PXR/CYP3A4-humanized mice for studying drug-drug interactions involving intestinal P-glycoprotein. Mol Pharm 10:1056-62
Patterson, Andrew D; Slanar, Ondrej; Krausz, Kristopher W et al. (2009) Human urinary metabolomic profile of PPARalpha induced fatty acid beta-oxidation. J Proteome Res 8:4293-300
Cheng, Jie; Ma, Xiaochao; Krausz, Kristopher W et al. (2009) Rifampicin-activated human pregnane X receptor and CYP3A4 induction enhance acetaminophen-induced toxicity. Drug Metab Dispos 37:1611-21
Liu, Aiming; Patterson, Andrew D; Yang, Zongtao et al. (2009) Fenofibrate metabolism in the cynomolgus monkey using ultraperformance liquid chromatography-quadrupole time-of-flight mass spectrometry-based metabolomics. Drug Metab Dispos 37:1157-63
Cho, Joo-Youn; Kang, Dong Wook; Ma, Xiaochao et al. (2009) Metabolomics reveals a novel vitamin E metabolite and attenuated vitamin E metabolism upon PXR activation. J Lipid Res 50:924-37
Dostalek, Miroslav; Hardy, Klarissa D; Milne, Ginger L et al. (2008) Development of oxidative stress by cytochrome P450 induction in rodents is selective for barbiturates and related to loss of pyridine nucleotide-dependent protective systems. J Biol Chem 283:17147-57
Dragin, Nadine; Shi, Zhanquan; Madan, Rajat et al. (2008) Phenotype of the Cyp1a1/1a2/1b1-/- triple-knockout mouse. Mol Pharmacol 73:1844-56
Smith, N F; Baker, S D; Gonzalez, F J et al. (2008) Modulation of erlotinib pharmacokinetics in mice by a novel cytochrome P450 3A4 inhibitor, BAS 100. Br J Cancer 98:1630-2
Chen, Chi; Shah, Yatrik M; Morimura, Keiichirou et al. (2008) Metabolomics reveals that hepatic stearoyl-CoA desaturase 1 downregulation exacerbates inflammation and acute colitis. Cell Metab 7:135-47

Showing the most recent 10 out of 83 publications